Tenax Therapeutics Inc. (TENX) posted a Q4 2025 net loss of $0.38 per share. The clinical-stage pharmaceutical company develops novel cardiopulmonary therapies in the United States.
Tenax’s pipeline includes TNX-101, TNX-102, and TNX-103 (levosimendan), which have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension. The company also develops TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
The company operates in the specialty pharmaceutical sector, focused on cardiovascular and pulmonary conditions.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Tenax Therapeutics Inc (TENX) Reports Q4 Earnings first appeared on Alphastreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
